NCT05987826 2023-08-14
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage â…¡-â…¢B EGFR Sensitive Mutant NSCLC
Shanghai Zhongshan Hospital
Phase 2 Unknown
Clinical Trials
8 trialsNCT04895930 2023-01-06
FOCUS-A
Shanghai Chest Hospital
Phase 2 Unknown
NCT05548348 2022-09-21
First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation
Chongqing University Cancer Hospital
Phase 2 Unknown
NCT05255406 2022-08-04
Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)
Fudan University
Phase 2 Unknown
NCT05209256 2022-01-26
Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2/3 Unknown
NCT05165355 2022-01-18
ATHEM
Tongji University
Phase 2 Unknown
NCT05079022 2021-10-15
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
Peking University People's Hospital
Phase 1/2 Unknown
NCT04970693 2021-07-21
A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression
Sun Yat-sen University
Phase 2 Unknown